Olopatadine
Active ingredient · 2 therapeutic classes
Sold as Opatanol · PAZEO · PATANOL · PATADAY
- Drug class
- Antiallergic Agents, Excl. Corticosteroids
- Availability
- Prescription and OTC
- Routes
- Ophthalmic, Nasal
- Markets covered
- 4
- Products on record
- 40
Overview
Olopatadine is an active pharmaceutical ingredient in the Antiallergic Agents, Excl. Corticosteroids group (R01AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 14 | May 15, 2026 |
| US United States | FDA | 13 | April 22, 2026 |
| CA Canada | Health Canada | 12 | October 23, 2025 |
| EU European Union | EMA | 1 | January 22, 2026 |
GBUnited Kingdom· MHRA
14 products
Uses
Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.
How to take
USUnited States· FDA
13 products
Uses
USES temporarily relieves itchy and red eyes due to pollen, ragweed, grass, animal hair and dander
How to take
CACanada· Health Canada
12 products
Uses
PATADAY® (olopatadine hydrochloride ophthalmic solution) is indicated for: • the treatment of ocular itching associated with seasonal allergic conjunctivitis. 1 Pediatrics Paediatrics (<18 years): The effectiveness of PATADAY has not been established in paediatric patients <18 years of age.
No overall difference in safety has been observed between paediatric and adult patients. 2 Geriatrics Geriatrics: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
How to take
EUEuropean Union· EMA
1 product
Uses
Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.
How to take
Drug interactions
Known interactions involving Olopatadine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 370. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL252980125 · revised May 30, 2025
- [2]FDA DailyMed · 02c27305-b2e8-ae… · revised December 10, 2025 [PDF]
- [3]Health Canada (DPD) · 02362171 · revised March 22, 2025
- [4]European Medicines Agency · EMEA/H/C/000407 · revised January 22, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.